Your session is about to expire
← Back to Search
Small Molecule
PRLX 93936 for Multiple Myeloma
Phase 1 & 2
Waitlist Available
Led By Paul Richardson, MD
Research Sponsored by Prolexys Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of first dose to date of response, assessed up to 8 months
Awards & highlights
Study Summary
To determine the maximum tolerated dose of, and response to, PRLX 93936 as treatment for patients with relapsed or relapsed/refractory multiple myeloma.
Eligible Conditions
- Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from date of first dose to date of response, assessed up to 8 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of first dose to date of response, assessed up to 8 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximum Tolerated Dose
Secondary outcome measures
Duration of response
Response to treatment
Time to progression
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: PRLX 93936Experimental Treatment1 Intervention
PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRLX 93936
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Prolexys PharmaceuticalsLead Sponsor
1 Previous Clinical Trials
37 Total Patients Enrolled
Paul Richardson, MDPrincipal InvestigatorDana-Farber Cancer Institute
11 Previous Clinical Trials
802 Total Patients Enrolled
10 Trials studying Multiple Myeloma
651 Patients Enrolled for Multiple Myeloma
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger